Preclinical Development
Russell Scammell
Director Small Molecule Drug Discovery
Charles River Laboratories
Harlow, England, United Kingdom
Darren Matthews
Research Leader
Charles River Laboratories
Greater Brighton, England, United Kingdom
Description: Preformulation and formulation development are traditionally prioritized at the later stages of the drug discovery process, which can present downstream challenges in the developability of an API. This can have a significant impact on the API performance, resulting in delays and higher development costs.
This presentation provides an overview of how integrating key disciplines and assays into the early preclinical development process and collaboration in the CMC space can accelerate timelines while reducing white space in the journey from preclinical to clinical studies.